Amgen Korea announced on the 15th that the Ministry of Food and Drug Safety approved its ‘Lumakras (sotorasib)’ for the treatment of KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer on the 15th.

Lumakras is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy.

With the approval, Lumakras became the first targeted therapy to be approved by the MFDS for KRAS G12C NSCLC patients. KRAS is one of the major oncogenes that is found in various cancers including NSCLC. It is the second-most common mutation that occurs in Asian patients afte